Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc.
July 10, 2019 13:03 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr”) (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc....
Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019
July 03, 2019 10:00 ET
|
Ohr Pharmaceutical, Inc.
-- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal-- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting-- Every...
Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Quarter of 2019
May 15, 2019 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019....
Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements
February 21, 2019 10:45 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained...
Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019
February 14, 2019 16:05 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three months ended December 31, 2018. “Since we...
Ohr Pharmaceutical Announces Reverse Stock Split to be Effective February 4, 2019
January 23, 2019 16:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (Nasdaq: OHRP) announced today that its board of directors has determined to effect a one-for-twenty...
Ohr Pharmaceutical, Inc. Announces Merger Agreement with NeuBase Therapeutics, Inc.
January 03, 2019 06:30 ET
|
Ohr Pharmaceutical, Inc.
Proposed combined company's peptide-nucleic acid antisense oligonucleotide (PATrOL™) technology platform enables rapid development of therapies delivered systemically for genetic diseases Initial...
Ohr Pharmaceutical Reports Fiscal Third Quarter 2018 Financial Results
August 14, 2018 16:05 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its...
Ohr Pharmaceutical Reports Fiscal Second Quarter 2018 Financial Results
May 15, 2018 16:05 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its...
Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results
February 14, 2018 16:05 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results and...